Supply for Antiviral Remdesivir is Meeting U.S. Demands


Remdesivir can Now Be Bought Directly From the Company

Health Editor’s Note: Gilead is able to keep production of remdesivir (veklury) up and is meeting demand for this antiviral in the U.S. Remdesivir is currently authorized for Temporary use under an Emergency Use Authorization (EUA) for treatment of COVID-19 patients in the hospital, moderate to severe disease, regardless of the need for supplemental oxygen.  

“Veklury has broad-spectrum antiviral activity both in vitro and in vivo in animal models against multiple emerging viral pathogens, including Ebola, SARS, Marburg, MERS and SARS-CoV-2, the virus that causes COVID-19. Data from three randomized, controlled clinical trials in hospitalized patients with COVID-19 have consistently demonstrated the clinical benefits of treatment with Veklury. In the placebo-controlled ACTT-1 study, Veklury significantly improved time to recovery and also reduced the likliehood of progression of the disease.”

At this point I am wondering what more this drug needs to do to be considered acceptable treatment for COVID-19? The only potential difficulty I see in the use of remdesivir is that it has to be administered by IV  (one dose and then a loading dose daily for up to 10 days) which limits who can administer it. ……Carol 


Due to the nature of independent content, VT cannot guarantee content validity.
We ask you to Read Our Content Policy so a clear comprehension of VT's independent non-censored media is understood and given its proper place in the world of news, opinion and media.

All content is owned by author exclusively. Expressed opinions are NOT necessarily the views of VT, other authors, affiliates, advertisers, sponsors, partners or technicians. Some content may be satirical in nature. All images within are full responsibility of author and NOT VT.

About VT - Read Full Policy Notice - Comment Policy